首页> 中文期刊> 《现代肿瘤医学》 >甲羟孕酮治疗去势抵抗型前列腺癌的疗效观察

甲羟孕酮治疗去势抵抗型前列腺癌的疗效观察

         

摘要

Objective:To observe the efficacy and side effects of medroxyprogesterone in castrate -resistant pros-tate cancer (CRPC).Methods:PSA,KPS score,hemoglobin,nutritional status,and drug toxicity were evaluated in 62 CRPC patients before and after orally taking medroxyprogesterone.Results:After orally taking medroxyprogesterone, PSA decreased in 7 patients(11.3%),and remained stable in 15 patients(24.2%).KPS score and hemoglobin were improved significantly (P <0.05).The nutritional status were improved in 40 patients(64.5%),and remained stable in 19 patients(30.6%).No III -IV grade toxic and side effects were found.Six patients had mild hyponatremia,five patients had mild hypokalemia,four patients had Ⅰdegree lower limb edema after treatment.Conclusion:Medroxypro-gesterone may slow the progression of the PSA,improve the quality of life with few drug side effects in advanced CRPC patients.%目的:观察甲羟孕酮对于去势抵抗型前列腺癌(CRPC)的疗效及毒副反应。方法:观察62例 CRPC患者口服甲羟孕酮后,对比口服药物前后 PSA、生活质量 KPS 评分、血红蛋白、营养状况的变化,评价药物毒副反应。结果:62例患者经过口服甲羟孕酮后,PSA 下降的有效率为11.3%、稳定率达24.2%。KPS 评分、血红蛋白较前明显改善(P 值均<0.05)。营养状况的改善率为64.5%、稳定率达30.6%。未发现 III -IV 级毒副反应,6例出现轻度低钠血症,5例出现轻度低钾血症,Ⅰ度下肢水肿较治疗前增加4例。结论:甲羟孕酮可延缓部分 CRPC 患者的 PSA 进展,改善晚期肿瘤患者的生活质量,毒副反应小。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号